首頁 > 市場調查報告書 > 製藥

眼科藥物

市場調查報告書

商品編碼

1547536

全球視網膜疾病治療市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測

Global Retinal Disorders Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年07月01日 | 出版商:

Value Market Research | 英文 170 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球視網膜疾病治療市場的需求預計將從2023年的193.9億美元達到2032年近450.6億美元的市場規模，2024-2032年研究期間的複合年成長率為9.82%。

視網膜是位於眼睛後端的敏感組織層，負責光感測並將影像傳輸到大腦，任何形式的視網膜疾病都可能損害這種脆弱的組織並影響視力，在嚴重的情況下，導致失明。視網膜疾病可能與遺傳或年齡有關，導致視力退化。然而，視網膜檢查是診斷潛在疾病和視網膜遺傳性疾病基因檢測的第一步。

市場動態

全球成人和糖尿病患者人數的增加將推動視網膜疾病治療市場的發展。此外，隨著已開發國家和發展中國家視網膜疾病的盛行率不斷增加，發展中國家研發活動的增加必將推動全球市場的成長。此外，政府和非營利組織提供的支持的增加可能會對市場產生積極影響。此外，用於視網膜疾病治療的各種管道產品也將推動全球視網膜疾病治療市場的成長。然而，視網膜治療的高昂成本以及雷射眼科治療後出現短期副作用和感染和發炎等長期併發症的患者抱怨可能會影響全球視網膜疾病治療市場的成長。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具還對全球視網膜疾病治療市場的每個細分市場進行了包容性評估。視網膜疾病治療產業的成長和趨勢為本研究提供了整體方法。

市場區隔

視網膜疾病治療市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略家確定相應產品或服務的目標人口統計數據以及即將到來的機會。

按類型

黃斑部病變
乾性黃斑部病變
濕性黃斑部病變
糖尿病視網膜病變
其他

按劑量

凝膠
眼睛解決方案
膠囊和片劑
眼藥水
藥膏

按配銷通路

醫院藥房
網路藥房
零售藥房
視網膜疾病治療

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲視網膜疾病治療市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。視網膜疾病治療市場的主要參與者包括 Santen Pharmaceutical Co. Ltd.、Regeneron Pharmaceuticals Inc.、Graybug Vision Inc.、Shire（Takeda Pharmaceutical Company Limited）、Bayer AG、Genentech Inc.、Acuela Inc.、Pfizer Inc.、久保田製藥控股有限公司、艾爾建公司。（艾伯維公司）。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區按國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲按國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 9 章：視網膜疾病治療公司的競爭格局

視網膜疾病治療市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 10 章：公司簡介

頂級公司市佔率分析
市場集中度
Santen Pharmaceutical Co. Ltd.

公司概況
公司收入
產品
最新動態

Regeneron Pharmaceuticals Inc.

公司概況
公司收入
產品
最新動態

Graybug Vision Inc.

公司概況
公司收入
產品
最新動態

Shire (Takeda Pharmaceutical Company Limited)

公司概況
公司收入
產品
最新動態

Bayer AG

公司概況
公司收入
產品
最新動態

Genentech Inc.

公司概況
公司收入
產品
最新動態

Acucela Inc.

公司概況
公司收入
產品
最新動態

Pfizer Inc.

公司概況
公司收入
產品
最新動態

Kubota Pharmaceutical Holdings Co. Ltd.

公司概況
公司收入
產品
最新動態

Allergan Plc. (AbbVie Inc.)

公司概況
公司收入
產品
最新動態

註 - 在公司概況中，財務詳細資訊和最新發展視情況而定，或對私人公司而言可能不包括在內

簡介目錄圖表

Product Code: VMR11215030

The global demand for Retinal Disorders Treatment Market is presumed to reach the market size of nearly USD 45.06 Billion by 2032 from USD 19.39 Billion in 2023 with a CAGR of 9.82% under the study period 2024-2032.

The retina is a sensitive layer of tissue located at the back end of the eyes and is responsible for light sensing and transferring images to the brain, any form of the retinal disorder may damage this delicate tissue and affect vision, and, in severe cases, lead to blindness. Retinal disorders may be genetic or age-related, causing degenerative changes in vision. However, a retinal examination is the first step in diagnosing the potential disease and genetic testing for retinal genetic disorders.

MARKET DYNAMICS

The rise in adult and diabetic patient's population across the globe will boost the retinal disease therapeutics market. In addition, the increase in R&D activities in developing countries is bound to boost the market growth globally as the prevalence of the retinal disorder is increasing in both developed and developing regions. Further, the rise in the support offered by government and non-profitable organizations may have a positive impact on the market. In addition, various pipeline products for retinal disorder treatment will also propel the global retinal disease therapeutics market to grow. However, the high cost of retina treatment therapies and patient complaints as having experienced short-term side effects and long-term complications as infection and inflammation after laser eye treatment may affect the global retinal disease therapeutics market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Retinal Disorders Treatment. The growth and trends of Retinal Disorders Treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Retinal Disorders Treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

Macular Degeneration
Dry Macular Degeneration
Wet Macular Degeneration
Diabetic Retinopathy
Others

By Dosage

Gels
Eye Solutions
Capsules & Tablets
Eye Drops
Ointments

By Distribution Channel

Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
Retinal Disorder Treatment

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Retinal Disorders Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Retinal Disorders Treatment market include Santen Pharmaceutical Co. Ltd., Regeneron Pharmaceuticals Inc., Graybug Vision Inc., Shire (Takeda Pharmaceutical Company Limited), Bayer AG, Genentech Inc., Acucela Inc., Pfizer Inc., Kubota Pharmaceutical Holdings Co. Ltd., Allergan Plc. (AbbVie Inc.). This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. RETINAL DISORDERS TREATMENT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By Dosage
- 3.7.3 Market Attractiveness Analysis By Distribution Channel
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL RETINAL DISORDERS TREATMENT MARKET ANALYSIS BY TYPE

5.1. Overview By Type
5.2. Historical and Forecast Data
5.3. Analysis By Type
5.4. Macular Degeneration Historic and Forecast Sales By Regions
5.5. Dry Macular Degeneration Historic and Forecast Sales By Regions
5.6. Wet Macular Degeneration Historic and Forecast Sales By Regions
5.7. Diabetic Retinopathy Historic and Forecast Sales By Regions
5.8. Others Historic and Forecast Sales By Regions

6. GLOBAL RETINAL DISORDERS TREATMENT MARKET ANALYSIS BY DOSAGE

6.1. Overview By Dosage
6.2. Historical and Forecast Data
6.3. Analysis By Dosage
6.4. Gels Historic and Forecast Sales By Regions
6.5. Eye Solutions Historic and Forecast Sales By Regions
6.6. Capsules & Tablets Historic and Forecast Sales By Regions
6.7. Eye Drops Historic and Forecast Sales By Regions
6.8. Ointments Historic and Forecast Sales By Regions

7. GLOBAL RETINAL DISORDERS TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

7.1. Overview By Distribution Channel
7.2. Historical and Forecast Data
7.3. Analysis By Distribution Channel
7.4. Hospital Pharmacy Historic and Forecast Sales By Regions
7.5. Online Pharmacy Historic and Forecast Sales By Regions
7.6. Retail Pharmacy Historic and Forecast Sales By Regions
7.7. Retinal Disorder Treatment Historic and Forecast Sales By Regions

8. GLOBAL RETINAL DISORDERS TREATMENT MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE RETINAL DISORDERS TREATMENT COMPANIES

9.1. Retinal Disorders Treatment Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF RETINAL DISORDERS TREATMENT INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Santen Pharmaceutical Co. Ltd.
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Regeneron Pharmaceuticals Inc.
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Graybug Vision Inc.
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. Shire (Takeda Pharmaceutical Company Limited)
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Bayer AG
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Genentech Inc.
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Acucela Inc.
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. Pfizer Inc.
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Kubota Pharmaceutical Holdings Co. Ltd.
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. Allergan Plc. (AbbVie Inc.)
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments